Comparative Pharmacology
Head-to-head clinical analysis: CHLOROTHIAZIDE versus HYDRO RIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROTHIAZIDE versus HYDRO RIDE.
CHLOROTHIAZIDE vs HYDRO-RIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
500 mg to 1000 mg orally or intravenously once or twice daily.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
None Documented
None Documented
Terminal half-life: 45–120 minutes (prolonged in renal impairment); clinical context: short duration requires frequent dosing
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateChlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateTerminal half-life 4-6 hours (prolonged in renal impairment).
Renal: ~95% (tubular secretion); Fecal: <5%
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Chlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin."